IMVIQOTCHealthcare · Biotechnology

IMV Inc.

$0.00-90.00%($-0.00)

TickerSpark Score

49/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMVIQ research report →

52-Week Range0% of range

Low $0.00

Current $0.00

High $1.00

Companywww.imv-inc.com

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers.

CEO: Andrew Hall
IPO: 2009
Employees: 63
HQ: Dartmouth, NS, CA

Price Chart

-100.00% · this period

Valuation

Market Cap: $117
P/E: -0.18
P/S: 0.00
P/B: -1.03
EV/EBITDA: -0.47
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -495.17%
ROIC: -172.47%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-37,991,000 · -3.83%
EPS: $-4.55 · 7.71%
Op Income: $-39,494,000
FCF YoY: -3.06%

Performance & Tape

52W High: $1.00
52W Low: $0.00
50D MA: $0.00
200D MA: $0.03
Beta: 1.19
Avg Volume: 8.80K

Get TickerSpark's AI analysis on IMVIQ

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime